55.53
0.78%
+0.43
After Hours:
55.53
LivaNova PLC stock is currently priced at $55.53, with a 24-hour trading volume of 544.73K.
It has seen a +0.78% increased in the last 24 hours and a +2.10% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $55.07 pivot point. If it approaches the $55.87 resistance level, significant changes may occur.
Previous Close:
$55.10
Open:
$55.15
24h Volume:
544.73K
Market Cap:
$3.00B
Revenue:
$1.15B
Net Income/Loss:
$17.55M
P/E Ratio:
1,110.60
EPS:
0.05
Net Cash Flow:
$39.93M
1W Performance:
+6.12%
1M Performance:
+2.10%
6M Performance:
+17.85%
1Y Performance:
+15.23%
LivaNova PLC Stock (LIVN) Company Profile
Name
LivaNova PLC
Sector
Industry
Phone
44 2033 250 660
Address
20 Eastbourne Terrace, London
LivaNova PLC Stock (LIVN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-06-23 | Initiated | HSBC Securities | Hold |
Jul-19-23 | Initiated | Robert W. Baird | Neutral |
Apr-14-23 | Initiated | Mizuho | Neutral |
Dec-21-22 | Initiated | Barclays | Equal Weight |
Apr-06-22 | Initiated | Wolfe Research | Outperform |
Feb-24-22 | Upgrade | UBS | Neutral → Buy |
Dec-03-21 | Initiated | Goldman | Buy |
Aug-20-21 | Reiterated | Needham | Buy |
Jul-20-21 | Upgrade | Needham | Hold → Buy |
Mar-03-21 | Downgrade | Berenberg | Buy → Hold |
Jan-05-21 | Downgrade | Needham | Buy → Hold |
Sep-02-20 | Initiated | Robert W. Baird | Outperform |
Jun-26-20 | Reiterated | Needham | Buy |
Oct-30-19 | Reiterated | Needham | Buy |
Feb-28-19 | Reiterated | Needham | Buy |
Nov-28-18 | Initiated | UBS | Neutral |
Aug-02-18 | Reiterated | Needham | Buy |
Jun-08-18 | Initiated | Stifel | Buy |
May-31-18 | Reiterated | Needham | Buy |
Feb-28-18 | Reiterated | Needham | Buy |
View All
LivaNova PLC Stock (LIVN) Latest News
Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline
Zacks Investment Research
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
Zacks Investment Research
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
Zacks Investment Research
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why International Flavors & Fragrances Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
LivaNova PLC Stock (LIVN) Financials Data
LivaNova PLC (LIVN) Revenue 2024
LIVN reported a revenue (TTM) of $1.15 billion for the quarter ending December 31, 2023, a +12.89% rise year-over-year.
LivaNova PLC (LIVN) Net Income 2024
LIVN net income (TTM) was $17.55 million for the quarter ending December 31, 2023, a +120.34% increase year-over-year.
LivaNova PLC (LIVN) Cash Flow 2024
LIVN recorded a free cash flow (TTM) of $39.93 million for the quarter ending December 31, 2023, a -8.00% decrease year-over-year.
LivaNova PLC (LIVN) Earnings per Share 2024
LIVN earnings per share (TTM) was $0.32 for the quarter ending December 31, 2023, a +119.75% growth year-over-year.
LivaNova PLC Stock (LIVN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Hebbelinck Trui | Chief Human Resources Officer |
Mar 30 '24 |
Option Exercise |
0.00 |
11,779 |
0 |
19,320 |
Shvartsburg Alex | CFO |
Mar 30 '24 |
Option Exercise |
0.00 |
14,752 |
0 |
24,133 |
Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '24 |
Option Exercise |
0.00 |
1,478 |
0 |
2,828 |
KOZY WILLIAM A | Chairman and CEO |
Feb 29 '24 |
Option Exercise |
0.00 |
14,512 |
0 |
32,333 |
Saia Andrea Lynn | Director |
Dec 31 '23 |
Option Exercise |
0.00 |
1,468 |
0 |
11,113 |
Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
2,254 |
0 |
2,254 |
Shvartsburg Alex | CFO |
Dec 15 '23 |
Option Exercise |
0.00 |
613 |
0 |
9,548 |
KOZY WILLIAM A | Director |
Oct 14 '23 |
Option Exercise |
0.00 |
10,311 |
0 |
21,550 |
Story Brooke | Director |
Sep 15 '23 |
Option Exercise |
0.00 |
1,725 |
0 |
1,725 |
Hebbelinck Trui | Chief Human Resources Officer |
Sep 15 '23 |
Option Exercise |
0.00 |
440 |
0 |
7,748 |
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression. The company's product portfolio also includes various strategic portfolio initiatives, such as transcatheter mitral valve replacement, an implant device for the treatment of mitral regurgitation through the replacement of native mitral valve; VITARIA to treat heart failure through VNS; and ANTHEM-HFpEF to study autonomic regulation therapy in patients experiencing symptomatic heart failure with preserved ejection fraction, as well as treatment resistant depression. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Cap:
|
Volume (24h):